They are Wuxi pharmacuticals. They are one of the 50 fastest growing companies in China and they have an ADR that trades in the US. They mainly do all the clinical trials for big US pharma companies. They are still pretty small and thier last quarter was good but not blowout. It went from 30 down to 22 and now it is back to 31. Does anyone consider this a buy? I do not own any of this stock so any technical analysis would be great.

Stock is #22 on the IBD top 100 this week. Comment below chart notes: "Rebounding from 52% correction. But few big buyers".+66% Annual EPSLast quarter EPS +200%Prior quarter EPS +500%debt = 999%PE 72